Adamed across the globe

Global development

A consistently implemented development strategy based on two pillars – innovation and international expansion – has made the pharmaceutical and biotechnology company Adamed a renowned global brand.

We started our international expansion in 2003. Today, our products are available to patients in more than 70 countries around the world.
We operate branches in Spain, Russia, the Czech Republic, Vietnam, Italy, Kazakhstan, Uzbekistan, Slovakia and Ukraine. 
In Vietnam, we consistently implement the transfer of technology and knowledge. We have been EU-GMP certified since August 2022.
For many years, we have recorded a steady increase in the volume and value of our product sales. International operations currently account for 36% of our business, and our development plans anticipate a further increase to more than 50% by 2027.


Adamed’s global development

The international expansion of our company is based on two business models

International markets
Poland (since 1986)
Adamed in Poland
Ukraine (since 2017)
Representative office website
Czech Republic (since 2016)
Representative office website
Slovakia (since 2016)
Representative office website
Italy (since 2019)
Representative office website
Spain (since 2009)
Representative office website
Russia (since 2012)
Representative office website
Kazakhstan (since 2013)
Representative office website
Uzbekistan (since 2020)
Representative office website
Vietnam (since 2018)
Representative office website
We started
in Poland
We now have 9 foreign
representative offices
Adamed’s products are
available around the world
Polish innovations
on a global scale
Learn more

Investments in Asia

At the end of 2017, Adamed acquired a majority stake in the local pharmaceutical company Davipharm, and in April 2023 the purchase transaction of the remaining 30 percent of shares was closed - thus Adamed became the sole owner of the Vietnamese company.

This investment is aimed at strengthening Davipharm's market position by introducing EU-GMP standards in the plant and allowing the company to compete with high-quality imported drugs at prices affordable to Vietnamese patients.

Through the purchase transaction 100 percent of shares in Davipharm, Adamed is building a strong platform for further dynamic expansion in the Asia-Pacific area.


Ecupharma acquisition

In 2019, Adamed purchased a block of shares in the Italian company Ecupharma. We formed a strategic partnership with the company to support Adamed’s expansion in the Italian market of cardiac medications, and ultimately also in otherareas of therapy.

Ecupharma is a rapidly growing pharmaceutical company active in the fields of neuropsychiatry and urology. Its product portfolio addresses the needs of people with chronic ailments. The company consistently builds its market standing with the support of its loyal customers. Similarly to Adamed, the company also focuses on health conditions affecting the elderly, seeking to respond to contemporary demographic challenges.